Cytek Biosciences, Inc.: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 8, 2023 and accepted by EDGAR at Aug 8, 2023, 16:34 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $49.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2023-01-01 to 2023-06-30 | $86.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-04-01 to 2023-06-30 | $21.5m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2023-01-01 to 2023-06-30 | $37.6m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-04-01 to 2023-06-30 | $28.2m | us-gaap:GrossProfit |
| Gross profit | 6 months2023-01-01 to 2023-06-30 | $49.2m | us-gaap:GrossProfit |
| Research and development | 3 months2023-04-01 to 2023-06-30 | $12.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-01-01 to 2023-06-30 | $22.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-04-01 to 2023-06-30 | −$9.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-06-30 | −$21.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-04-01 to 2023-06-30 | $409.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2023-01-01 to 2023-06-30 | $1.1m | us-gaap:InterestExpense |
| Income tax | 3 months2023-04-01 to 2023-06-30 | −$2.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-01-01 to 2023-06-30 | −$4.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-04-01 to 2023-06-30 | −$4.4m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-06-30 | −$11.2m | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months2023-04-01 to 2023-06-30 | 135,918,707 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-01-01 to 2023-06-30 | 135,705,139 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-01-01 to 2023-06-30 | $8.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-01-01 to 2023-06-30 | $1.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-06-30 | $131.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-06-30 | $424.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $525.1m | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $53.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-06-30 | $100.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-06-30 | $424.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-039899. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.